新型冠状病毒感染治疗药物超说明书应用专家共识
该共识针对COVID-19救治中免疫治疗药物不熟悉、特殊人群(如吞咽困难、严重肾功能不全)用药及药物可及性问题,组织多学科专家制定超说明书用药推荐。编写组汇总境内外药品说明书、COVID-19临床管理指南及高质量研究证据,参照Micromedex的Thomson有效性等级、推荐等级及证据强度分类,通过共识会议形成10条推荐意见,其中超说明书改变剂型给药3条、超适应证给药5条、超适用人群给药2条,旨在为临床医生提供合理用药依据并为药学部门管理提供参考。
要点
- 共识形成10条超说明书用药推荐:改变剂型给药3条、超适应证给药5条、超适用人群给药2条。
- 超适应证包括:托珠单抗或巴瑞替尼静脉注射用于重型或危重型COVID-19患者。
- 无法获得静脉托珠单抗或巴瑞替尼片时,可皮下注射托珠单抗用于重型或危重型患者。
- 托珠单抗和巴瑞替尼均不可及时,可改用托法替布10 mg每日两次。
- 甲泼尼龙或泼尼松用于重型或危重型COVID-19患者以降低全因死亡率。
适用人群与场景
- 新型冠状病毒感染(COVID-19)救治中涉及免疫治疗药物、特殊人群(如吞咽困难、严重肾功能不全的患者等)用药及药物可及性问题的患者。
处置流程与药物剂量
- 超说明书改变剂型给药:将奈玛特韦-利托那韦片溶解为混悬液用于口服或胃管饲入给药。
- 超说明书改变剂型给药:为莫诺拉韦胶囊制备溶液。
- 超说明书改变剂型给药:将分散的巴瑞替尼片制成溶液。
- 超适应证给药:托珠单抗或巴瑞替尼静脉注射用于重型或危重型COVID-19患者。
- 超适应证给药:无法获得静脉托珠单抗或巴瑞替尼片时,皮下注射托珠单抗用于重型或危重型COVID-19患者。
- 超适应证给药:托珠单抗和巴瑞替尼均不可及时,改用托法替布10 mg每日两次。
- 超适应证给药:甲泼尼龙或泼尼松用于重型或危重型COVID-19患者以降低全因死亡率。
- 超适用人群给药:严重肾功能不全的COVID-19患者使用托珠单抗无需调整剂量。
研究设计与关键结果
- 编写组组织多学科专家,汇总境内外药品说明书、COVID-19临床管理指南及高质量研究证据,参照Micromedex的Thomson有效性等级、推荐等级及证据强度分类,通过共识会议形成10条超说明书用药推荐意见。
- 10条推荐中,超说明书改变剂型给药3条,超适应证给药5条,超适用人群给药2条。
证据类型、等级与局限
- 证据类型:专家共识;参照Micromedex的Thomson有效性等级、推荐等级及证据强度分类。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识旨在为临床医生提供COVID-19治疗药物合理用药依据,并为药学部门管理提供参考。
- 对吞咽困难或需胃管饲入的患者,可参考共识将奈玛特韦-利托那韦片溶解为混悬液、莫诺拉韦胶囊制备溶液、巴瑞替尼片制成溶液给药。
- 对重型或危重型COVID-19患者,在药物可及性受限时,可参考共识选择托珠单抗或巴瑞替尼静脉注射、皮下注射托珠单抗或托法替布10 mg每日两次。
- 对严重肾功能不全且eGFR 15-30 ml/(min·1.73m2)的重型或危重型患者,可参考共识调整巴瑞替尼为2 mg隔日一次或1 mg每日一次,托珠单抗无需调整剂量。
指南或共识出处
- 新型冠状病毒感染主要治疗药物超说明书应用专家共识(Zhonghua Jie He He Hu Xi Za Zhi)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The challenges for clinical management of coronavirus disease 2019 (COVID-19) consist of the unfamiliarity of immunomodulator prescription, the difficulty in drug administration in special patient populations (e.g., patients with dysphagia or severe renal insufficiency) and limited medication accessibility. Off-label administration of some medications for COVID-19 has been documented. Here, we highlight several issues pertinent to the clinical application of COVID-19 medications by soliciting multidisciplinary experts. We aggregated the drug specifications from and outside mainland China, the guidelines for clinical management of COVID-19 and the evidence from high-quality research. Recommendations were formed through teleconference with the consensus conference method by taking into account the levels of effectiveness and recommendation, and the strength of evidence of the Thomson Micromedex. We have formulated 10 recommendations for off-label drug administration, including three recommendations for off-label modification of drug dosage form for oral or gastric tube feeding administration (dissolving nirmatrelvir-ritonavir tablets into suspension, solution preparation for monulpiravir capsules, and solution of dispersed baricitinib tablets), five recommendations for off-indication use (intravenous injection of tocilizumab or baricitinib for severe or critically ill patients with COVID-19, subcutaneous injection of tocilizumab for severe or critically ill patients with COVID-19 in case of inaccessible intravenous tocilizumab or baricitinib tablets, substitution with tofacitinib 10 mg twice daily in case of the inaccessibility of tocilizumab and baricitinib; Methylprednisolone or prednisone for severe or critically ill patients with COVID-19 to reduce all-cause mortality), and two recommendations for off-label use among the targeted populations (no titration of tocilizumab doses for COVID-19 patients with severe renal insufficiency, baricitinib 2 mg once every other day or 1 mg daily for severe or critically ill patients with severe renal insufficiency and eGFR 15-30 ml/(min·1.73m2)). This consensus document aims to provide the reference for rational use of medications among clinicians and the pharmacovigilance monitoring.
新型冠状病毒感染(COVID-19)救治过程中存在对免疫治疗药物不熟悉、特殊人群(如吞咽困难、严重肾功能不全的患者等)用药以及药物的可及性等问题,部分药物存在超说明书用药的现象。为此,“新型冠状病毒感染主要治疗药物超说明书应用专家共识”编写组组织多学科专家,基于循证医学证据,参照Micromedex的Thomson有效性等级、推荐等级及证据强度分类,通过共识会议最终形成10条超说明书用药推荐意见,其中超说明书改变剂型给药3条,超适应证给药5条,超适用人群给药2条,旨在为临床医生提供合理用药依据并为药学部门管理提供参考。.
参考来源
- [Expert consensus on off-label administration of drugs in COVID-19]. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36822581. doi:10.3760/cma.j.cn112147-20230127-00038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。